Exendin agonist compounds

• US 7,157,555 B1
• Filed: 08/06/1998
• Issued: 01/02/2007
• Est. Priority Date: 08/08/1997
• Status: Expired due to Fees

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Prickett, Kathryn Susan, Beeley, Nigel Robert Arnold
• Primary Examiner(s): BORIN, MICHAEL L
• Application Number:
  US10/181,102
• Time in Patent Office: 3,071 Days
• Field of Search: 530/324, 514/2, 514/12
• US Class Current: 530/324
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/57563 Vasoactive intestinal peptide [VIP]; Related peptides

Abstract

Novel exendin peptide compounds are provided.

Claims

1. An exendin peptide compound of SEQ. ID NO:

6.

2. The composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.

3. An exendin peptide compound of SEQ ID NO:

10.

4. The composition comprising a compound of claim 3 in a pharmaceutically acceptable carrier.